Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138- CD34- tumor stem-like cells in multiple myeloma-bearing mice

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1439-1449

  Yang, Cuiping ^a,c   Wang, Jing ^b   Chen, Dengyu ^a   Chen, Junsong ^a   Xiong, Fei ^b   Zhang, Hongyi ^a   Zhang, Yunxia ^b   Gu, Ning ^b   Dou, Jun ^a  

^a Medical School   (China)

^b SOUTHEAST UNIVERSITY   (China)

^c JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Fe3O4 nanoparticles; Multiple myeloma; Paclitaxel; Tumor stem cells

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CD34 ANTIGEN; FERRIC OXIDE; INTERLEUKIN 6; NANOPARTICLE; PACLITAXEL; PACLITAXEL FERRIC OXIDE NANOPARTICLE; SYNDECAN 1; UNCLASSIFIED DRUG; VINCRISTINE; CASPASE; DRUG CARRIER; MAGNETITE NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CD138- CD34- CANCER STEM CELL; CELL ACTIVITY; CELL INVASION; CELL ISOLATION; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG RELEASE; DRUG STABILITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PATHOLOGY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; TREATMENT DURATION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; DRUG EFFECT; FE3O4 NANOPARTICLES; METABOLISM; NONOBESE DIABETIC MOUSE; SCID MOUSE; SURVIVAL; TUMOR CELL LINE; DRUG EFFECTS; SURVIVAL ANALYSIS;

MUS;

FE3O4 NANOPARTICLES; MULTIPLE MYELOMA; PACLITAXEL; TUMOR STEM CELLS;

ANIMALS; ANTIGENS, CD34; ANTINEOPLASTIC AGENTS; CASPASES; CELL LINE, TUMOR; DRUG CARRIERS; HUMANS; MAGNETITE NANOPARTICLES; MICE; MICE, INBRED NOD; MICE, SCID; MULTIPLE MYELOMA; NEOPLASTIC STEM CELLS; PACLITAXEL; SURVIVAL ANALYSIS; SYNDECAN-1;

EID: 84876222230     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S38447     Document Type: Article

References (38)

1. Agarwal JR, Matsui W. Multiple myeloma: a paradigm for translation of the cancer stem cell hypothesis. Anticancer Agents Med Chem. 2010;10: 116-120.
2. Vicente-Dueñas C, Romero-Camarero I, González-Herrero I, et al. A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J. 2012;31:3704-3717.
3. Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011;117:4409-4419.
4. Matsui W, Huff CA, Wang Q, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103:2332-2336.
5. Laubach J, Richardson P, Anderson K. Multiple myeloma. Annu Rev Med. 2011;62:249-264.
6. Martin W. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res. 2008;25:500-511.
7. Gindy ME, Prud'homme RK. Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy. Expert Opin Drug Deliv. 2009;6:865-878.
8. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 2008;26:57-64.
9. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-760.
10. Seo K, Chung SW, Byun Y, Kim D. Paclitaxel loaded nano-aggregates based on pH sensitive polyaspartamide amphiphilic graft copolymers. Int J Pharm. 2012;424:26-32.
11. Weeden C, Hartlieb KJ, Lim LY. Preparation and physicochemical characterization of a novel paclitaxel-loaded amphiphilic aminocalixarene nanoparticle platform for anticancer chemotherapy. J Pharm Pharmacol. 2012;64:1403-1411.
12. Letourneau I, Quinn MC, Wang LL, et al. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer. BMC Cancer. 2012;12:379.
13. Elsadek B, Kratz F. Impact of albumin on drug delivery-new applications on the horizon. J Control Release. 2012;157:4-28.
14. Qiu B, Sun X, Zhang D, Wang Y, Tao J, Ou S. TRAIL and paclitaxel synergize to kill U87cells and U87-derived stem-like cells in vitro. Int J Mol Sci. 2012;13:9142-9156.
15. Feng SS, Mu L, Win KY, Huang G. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem. 2004;11:413-424.
16. Oh KS, Lee S, Na JH, et al. Blood-pool multifunctional nanoparticles formed by temperature-induced phase transition for cancer-targeting therapy and molecular imaging. Int J Pharm. 2012;437:192-202.
17. Guan N, Liu C, Sun D, Xu J. A facile method to synthesize carboxyl-functionalized magnetic polystyrene nanospheres. Colloids Surf A. 2009;335:174-180.
18. Dou J, Pan M, Wen P, et al. Isolation and identification of cancer stem like cells from murine melanoma cell lines. Cell Mol Immunol. 2007;4: 467-472.
19. Marañón C, Planelles L, Alonso C, López MC. HSP70 from Trypanosoma cruzi is endowed with specific cell proliferation potential leading to apoptosis. Int Immunol. 2000;12:1685-1693.
20. Holt RU, Fagerli UM, Baykov V, et al. Hepatocyte growth factor promotes migration of human myeloma cells. Haematologica. 2008;93:619-622.
21. Cirstea D, Hideshima T, Rodig S, et al. Dual inhibition of Akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther. 2010;9:963-975.
22. Ponnusamy MP, Lakshmanan I, Jain M, et al. MUC4mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene. 2010;29:5741-5754.
23. Hu W, Wang J, Dou J, et al. Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice. Cell Transplant. 2011;20:669-680.
24. Yu F, Wang J, Dou J, et al. Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection. Nanomedicine. 2012;8: 1337-1344.
25. Brown CO, Salem K, Wagner BA, et al. Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase. Biochem J. 2012;444:515-527.
26. Hu K, Dou J, Yu F, et al. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1in mice. Vaccine. 2011;29:1455-1462.
27. He X, Wang J, Zhao F, et al. Antitumor efficacy of viable tumor vaccine modified by heterogenetic ESAT-6 antigen and cytokine IL-21in melanomatous mouse. Immunol Res. 2012;52:240-249.
28. Gou S, Liu T, Wang C, et al. Establishment of clonal colony-forming assay for propagation of pancreatic cancer cells with stem cell properties. Pancreas. 2007;34:429-435.
29. Stephens OW, Zhang Q, Qu P, et al. An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood. 2012;119:503-512.
30. Lin L, Benson DM Jr, DeAngelis S, et al. A small molecule, LLL12inhibits constitutive STAT3 and IL-6-induced STAT3signaling and exhibits potent growth suppressive activity in human multiple myeloma cells. Int J Cancer. 2012;130:1459-1469.
31. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. Interleukin-6signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012;38:904-910.
32. Ren Y, Zhang H, Chen B, et al. Multifunctional magnetic Fe3O4 nanoparticles combined with chemotherapy and hyperthermia to overcome multidrug resistance. Int J Nanomedicine. 2012;7:2261-2269.
33. Matsui W. Perspective: a model disease. Nature. 2011;480:S58.
34. Bommert K, Bargou R, Stuhmer T. Signaling and survival pathways in multiple myeloma. Eur J Cancer. 2006;42:1574-1580.
35. Reed JC, Pellecchia M. Apoptosis-based therapies for hematologic malignancies. Blood. 2005;106:408-418.
36. Gogvadze V, Orrenius S. Mitochondrial regulation of apoptotic cell death. Chem Biol Interact. 2006;163:4-14.
37. Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2in response to genotoxic stress. Science. 2004;304:843-846.
38. Kasibhatla S, Jessen KA, Maliartchouk S, et al. A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid. Proc Natl Acad Sci U S A. 2005;102:12095-12100.